How Pfizer used AI and supercomputers to design COVID-19 vaccine, tablet

Everything from molecular structure to freezer distribution involved ML, says tech chief

GTC AI algorithms were involved in every step of the way to design and deliver Pfizer's COVID-19 vaccine and antiviral tablets to hundreds of millions of people as coronavirus spread around the world.

Lidia Fonseca, Pfizer's chief digital and technology officer, said machine-learning technology was crucial in speeding up the pharma-goliath's processes to develop the vaccine: starting from drug discovery, to clinical trials, to supply chain management, to, finally, distribution to people.

Pfizer developed two weapons to fight COVID-19: a vaccine developed together with BioNTech, sold under the name Comirnaty, and the less common oral antiviral treatment, Paxlovid.

"We have clear examples in bringing both the vaccine, Comirnaty, and now the oral treatment, Paxlovid, to COVID breakthrough treatments to market in record time by harnessing the power of digital data in AI," she said in a conversation with Joe Ucuzoglu, chief executive officer at Deloitte US, on Tuesday at Nvidia's GPU Technology Conference.

Machine-learning models are well-suited for the task of finding novel molecules with a required set of properties. Scientists were able to sequence and piece together the structure of the coronavirus' spike protein early on in the pandemic. These spikes latch onto the surface of cells, where the coronavirus is absorbed and allowed to replicate. The host human then becomes infected, causing respiratory illness, fatigue, headaches, and other detrimental health effects.

An mRNA vaccine, like Pfizer's, works by teaching our cells to make just the spike protein part of the virus so that your immune system can learn to destroy such spikes on sight in future, thus hopefully eliminating the coronavirus should it enter the body.

Fonseca said Pfizer was able to design its mRNA-based vaccine and get it into clinical trials in just four months. Machine-learning algorithms helped the company predict yields during the manufacturing stage before tens of thousands of volunteers from six countries were recruited for testing. AI systems were used to analyse any discrepancies in the participants' symptoms.

"Additionally, we use both AI and machine learning to predict product temperatures, and enable preventative maintenance for the more than 3,000 freezers that house our vaccine doses. And we also leverage IoT and sensors to monitor and track vaccine shipments and temperatures at close to 100 per cent accuracy," she added.

By the time Pfizer turned its attention to making antiviral Paxlovid – which can be taken when symptoms begin to lessen the blow of the virus – scientists had a better idea of how to minimize allergic reactions observed in some people who had been injected with its vaccine. After their models generated a range of promising candidate molecules, they were able to test a fraction of them in virtual simulations run on supercomputers. 

"Many of the allergic reactions that clinical trial participants reported while testing our vaccine resulted from certain certain liquid lipid nanoparticles in the vaccine itself, using supercomputing we ran molecular dynamics simulations to find the right combination of lipid nanoparticle properties that reduce allergic reactions," Fonseca confirmed.

Pfizer reportedly turned to the MareNostrum 4 supercomputer to test potential new drugs virtually, according to HPC Wire. The big system is housed at the Barcelona Supercomputing Center, and has a ​​peak performance of 11.15 Petaflops; it contains 3,456 nodes each made up of two Intel Xeon Platinum 8160 processors and four Nvidia V100 GPUs.

Big Pharma is increasingly turning to AI. The technology automates processes over large scales, cutting costs, and reducing the time to get new drugs to market. Large manufacturers like Pfizer will have to work with smaller outfits specializing in areas the bigger businesses are weak in, such as data generation, aggregation, or analytics, Fonseca said.

"AI and machine learning powered data analytics are turbocharging drug discovery and development, but they can also help enhance prevention, early detection, personalized treatment and digital therapies. On the technology front, developments such as new gene therapies, digital therapeutics [will be] approved and reimbursable. Quantum computing capabilities will help bring breakthrough medicines to patients faster."

"I believe COVID-19 has accelerated these trends by as much as five years," she added. ®

Other stories you might like

  • Stolen university credentials up for sale by Russian crooks, FBI warns
    Forget dark-web souks, thousands of these are already being traded on public bazaars

    Russian crooks are selling network credentials and virtual private network access for a "multitude" of US universities and colleges on criminal marketplaces, according to the FBI.

    According to a warning issued on Thursday, these stolen credentials sell for thousands of dollars on both dark web and public internet forums, and could lead to subsequent cyberattacks against individual employees or the schools themselves.

    "The exposure of usernames and passwords can lead to brute force credential stuffing computer network attacks, whereby attackers attempt logins across various internet sites or exploit them for subsequent cyber attacks as criminal actors take advantage of users recycling the same credentials across multiple accounts, internet sites, and services," the Feds' alert [PDF] said.

    Continue reading
  • Big Tech loves talking up privacy – while trying to kill privacy legislation
    Study claims Amazon, Apple, Google, Meta, Microsoft work to derail data rules

    Amazon, Apple, Google, Meta, and Microsoft often support privacy in public statements, but behind the scenes they've been working through some common organizations to weaken or kill privacy legislation in US states.

    That's according to a report this week from news non-profit The Markup, which said the corporations hire lobbyists from the same few groups and law firms to defang or drown state privacy bills.

    The report examined 31 states when state legislatures were considering privacy legislation and identified 445 lobbyists and lobbying firms working on behalf of Amazon, Apple, Google, Meta, and Microsoft, along with industry groups like TechNet and the State Privacy and Security Coalition.

    Continue reading
  • SEC probes Musk for not properly disclosing Twitter stake
    Meanwhile, social network's board rejects resignation of one its directors

    America's financial watchdog is investigating whether Elon Musk adequately disclosed his purchase of Twitter shares last month, just as his bid to take over the social media company hangs in the balance. 

    A letter [PDF] from the SEC addressed to the tech billionaire said he "[did] not appear" to have filed the proper form detailing his 9.2 percent stake in Twitter "required 10 days from the date of acquisition," and asked him to provide more information. Musk's shares made him one of Twitter's largest shareholders. 

    Musk quickly moved to try and buy the whole company outright in a deal initially worth over $44 billion. Musk sold a chunk of his shares in Tesla worth $8.4 billion and bagged another $7.14 billion from investors to help finance the $21 billion he promised to put forward for the deal. The remaining $25.5 billion bill was secured via debt financing by Morgan Stanley, Bank of America, Barclays, and others. But the takeover is not going smoothly.

    Continue reading

Biting the hand that feeds IT © 1998–2022